-
2024Intestinal newborn regulatory B cell antibodies modulate microbiota communities., Cell Host Microbe 2024 Sep; (): .
-
2024Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells., Nat Med 2024 Sep; (): .
-
2024Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2., iScience 2024 Jul; 27(7): 110354.
-
2024[IgA antibodies against HIV-1]., Virologie (Montrouge) 2024 May; 0(0): .
-
2024Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells., Nat Commun 2024 Jan; 15(1): 178.
-
2023High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1., J Virol 2023 Dec; (): e0135123.
-
2023SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells., Nat Immunol 2023 Nov; (): .
-
2023TMPRSS2 is a functional receptor for human coronavirus HKU1., Nature 2023 Oct; (): .
-
2023HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria., Nat Commun 2023 Oct; 14(1): 6326.
-
2023Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure., Nat Commun 2023 Oct; 14(1): 6224.
-
2023Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller., Cell Host Microbe 2023 Jul; (): .
-
2023Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies., Nat Commun 2023 Feb; 14(1): 824.
-
2023Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants., iScience 2023 Feb; (): 106124.
-
2022Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters., Vaccines (Basel) 2022 Dec; 11(1): .
-
2022Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters, Vaccines (Basel).
-
2022Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies., Cell Rep Med 2022 Nov; (): 100850.
-
2022Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS-CoV-2., Protein Sci 2022 Nov; 31(11): e4447.
-
2022The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants., J Virol 2022 Oct; 96(19): e0130122.
-
2022IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies., Eur J Immunol 2022 Aug; (): .
-
2022NK cell spatial dynamics and IgA responses in gut-associated lymphoid tissues during SIV infections., Commun Biol 2022 Jul; 5(1): 674.
-
2022Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2., J Exp Med 2022 Jul; 219(7): .
-
2022SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but critical for productive class switch recombination., Nat Commun 2022 Jun; 13(1): 3707.
-
2022Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies., Nat Med 2022 Jun; 28(6): 1297-1302.
-
2022Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody., Proc Natl Acad Sci U S A 2022 May; 119(20): e2120976119.
-
2022An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa., Mol Ther 2022 Apr; (): .
-
2022Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers., Nat Commun 2022 Apr; 13(1): 1944.
-
2022Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2., EBioMedicine 2022 Mar; 77(): 103934.
-
2022Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller., J Exp Med 2022 Mar; 219(3): .
-
2022Advances in human monoclonal antibody therapy for HBV infection., Curr Opin Virol 2022 Feb; 53(): 101205.
-
2022Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells., Nat Commun 2022 02; 13(1): 630.
-
2022Considerable escape of SARS-CoV-2 Omicron to antibody neutralization., Nature 2022 Feb; 602(7898): 671-675.
-
2021SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation., EMBO J 2021 12; 40(24): e108944.
-
2021NK-B cell cross talk induces CXCR5 expression on natural killer cells., iScience 2021 Oct; 24(10): 103109.
-
2021Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2., J Infect Dis 2021 09; 224(6): 983-988.
-
2021Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection., Nat Immunol 2021 Sep; 22(11):1428-1439.
-
2021Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission., J Biol Chem 2021 10; 297(4): 101098.
-
2021A monocyte/dendritic cell molecular signature of SARS-CoV-2 related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis., Med (N Y) 2021 Aug; (): .
-
2021Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization., Nature 2021 08; 596(7871): 276-280.
-
2021Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies., Cell Rep Med 2021 05; 2(5): 100275.
-
2021Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies., Nat Med 2021 05; 27(5): 917-924.
-
2021Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis., PLoS Pathog 2021 04; 17(4): e1009526.
-
2021CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues., Front Immunol 2021 ; 12(): 695148.
-
2020Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models., Cell Host Microbe 2021 Feb 10;29(2):236-249: .
-
2020Syncytia formation by SARS-CoV-2-infected cells., EMBO J 2020 12; 39(23): e106267.
-
2020TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice., PLoS Pathog 2020 Nov; 16(11): e1009025.
-
2020Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier., mBio 2020 Oct; 11(5): .
-
2020A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations, Science Translational Medicine, 2020, 12 (559), pp.eabc3103. ⟨10.1126/scitranslmed.abc3103⟩.
-
2020Binding mechanisms of therapeutic antibodies to human CD20., Science 2020 Aug; 369(6505): 793-799.
-
2020Easy pan-detection of human IgA immunoglobulins., J. Immunol. Methods 2020 Aug; (): 112833.
-
2020Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3., EBioMedicine 2020 Jun; 57(): 102842.
-
2020Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers., J. Exp. Med. 2020 ; 217(10): .
-
2020MARVellous Sidekick Antibodies., Cell Host Microbe 2020 Jun; 27(6): 856-858.
-
2020Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5., J Virol 2020 02; 94(6): .
-
2020Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells., EMBO Rep 2020 02; 21(2): e49351.
-
2020[CRISPR-Cas9 editing of HIV-1 neutralizing human B cells], Med Sci (Paris) 2019 Dec;35(12):993-996.
-
2019TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses, J. Hepatol. 2019 Jul;.
-
2019HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells, Cell Rep 2019 Apr;27(2):572-585.e7.
-
2018A human immune system mouse model with robust lymph node development., Nat Methods 2018 08; 15(8): 623-630.
-
2018Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity, Cell Rep 2018 May;23(9):2568-2581.
-
2018Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1-Infected Individuals, J. Immunol. 2018 Apr;.
-
2017Humanized mouse models to study pathophysiology and treatment of HIV infection., Curr Opin HIV AIDS 2018 03; 13(2): 143-151.
-
2017Genetically intact but functionally impaired HIV-1 Env glycoproteins in the T-cell reservoir, J. Virol. 2017 Nov;.
-
2017What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1, Cold Spring Harb Perspect Biol 2017 Jun;.
-
2017Impact of Antigen Density on the Binding Mechanism of IgG Antibodies, Sci Rep 2017 Jun;7(1):3767.
-
2017HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection, EBioMedicine 2017 May;.
-
2017Hunting Down the HIV-1 Reservoir: A Starring Role for Antibodies?, Immunity 2017 Apr;46(4):527-529.
-
2017Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies, J. Virol. 2017 Apr;91(8).
-
2017Antibody 10-1074 suppresses viremia in HIV-1-infected individuals, Nat. Med. 2017 Jan;.
-
2016Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity, Mucosal Immunol 2016 Dec;.
-
2016[Antibodies that kill HIV-1-infected cells], Med Sci (Paris) 2016 8-9;32(8-9):671-4.
-
2016Scarcity of autoreactive human blood IgA(+) memory B cells, Eur. J. Immunol. 2016 Jul;.
-
2016Elimination of HIV-1-infected cells by broadly neutralizing antibodies, Nat Commun 2016 Mar;7:10844.
-
2016V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1, J. Acquir. Immune Defic. Syndr. 2016 Mar;71(3):237-45.
-
2015Tailored immunogens for rationally designed antibody-based HIV-1 vaccines, Trends Immunol. 2015 Jul;.
-
2015Efficient generation of human IgA monoclonal antibodies, J. Immunol. Methods 2015 Jul;422:102-10.
-
2015Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas, MBio 2015;6(2).
-
2015AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges, Nature 2015 Mar;519(7541):87-91.
-
2015Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient, J. Immunol. Methods 2015 Mar;418:61-5.
-
2014HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies, Science 2014 Dec;346(6215):1380-3.
-
2014Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies, J. Virol. 2014 Dec;88(23):13910-7.
-
2014Antibody B cell responses in HIV-1 infection, Trends Immunol. 2014 Nov;35(11):549-61.
-
2014Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques, J. Exp. Med. 2014 Sep;211(10):2061-74.
-
2014[HIV-1 cell-to-cell transmission and broadly neutralizing antibodies], Med Sci (Paris) 2014 May;30(5):508-10.
-
2013Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission, J. Exp. Med. 2013 Dec;210(13):2813-21.
-
2013Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia, Nature 2013 Nov;503(7475):277-80.
-
2013HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice, Proc. Natl. Acad. Sci. U.S.A. 2013 Oct;110(41):16538-43.
-
2013Antibodies in HIV-1 vaccine development and therapy, Science 2013 Sep;341(6151):1199-204.
-
2013HIV: Roadmaps to a vaccine, Nature 2013 Apr;496(7446):441-2.
-
2013Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization, Cell 2013 Mar;153(1):126-38.
-
2012Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies, Proc. Natl. Acad. Sci. U.S.A. 2012 Nov;109(47):E3268-77.
-
2012HIV therapy by a combination of broadly neutralizing antibodies in humanized mice, Nature 2012 Dec;492(7427):118-22.
-
2012Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein, J. Exp. Med. 2012 Jul;209(8):1469-79.
-
2012Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice, J. Exp. Med. 2012 May;209(5):1011-28.
-
2012Enhanced HIV-1 neutralization by antibody heteroligation, Proc. Natl. Acad. Sci. U.S.A. 2012 Jan;109(3):875-80.
-
2011Polyreactive antibodies in adaptive immune responses to viruses, Cell. Mol. Life Sci. 2012 May;69(9):1435-45.
-
2011Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells, Proc. Natl. Acad. Sci. U.S.A. 2011 Nov;108(44):18044-8.
-
2011Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses, PLoS ONE 2011;6(9):e24078.
-
2011Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding, Science 2011 Sep;333(6049):1633-7.
-
2010Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation, Nature 2010 Sep;467(7315):591-5.
-
2010Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness, J. Exp. Med. 2010 Aug;207(9):1995-2002.
-
2010Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity, J. Virol. 2010 May;84(10):5032-42.
-
2009Feedback control of regulatory T cell homeostasis by dendritic cells in vivo, J. Exp. Med. 2009 Aug;206(9):1853-62.
-
2009ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus, Arch Dermatol 2009 May;145(5):529-35.
-
2009Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals, Nature 2009 Apr;458(7238):636-40.
-
2008A method for identification of HIV gp140 binding memory B cells in human blood, J. Immunol. Methods 2009 Apr;343(2):65-7.
-
2008Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay, Clin. Immunol. 2008 Nov;129(2):304-12.
-
2008B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses, J. Invest. Dermatol. 2008 Dec;128(12):2859-69.
-
2008Expression of pemphigus-autoantigen desmoglein 1 in human thymus, Tissue Antigens 2008 May;71(5):464-70.
-
2007A single cycle of rituximab for the treatment of severe pemphigus, N. Engl. J. Med. 2007 Aug;357(6):545-52.
-
2006Immunogenetics of pemphigus: an update, Autoimmunity 2006 Nov;39(7):531-9.
-
2006A truncated alternative spliced isoform of human desmoglein 1 contains a specific T cell epitope binding to the pemphigus foliaceus-associated HLA class II DRbeta1*0102 molecule, J. Immunol. 2006 Nov;177(9):6517-26.
-
2006Proteomic analysis of the autoantibody response following immunization with a single autoantigen, Proteomics 2006 Sep;6(17):4829-37.
-
2005Genetic factors in pemphigus, J. Autoimmun. 2005 Jun;24(4):319-28.
-
2005[Molecular advances in pathogenesis of autoimmune blistering skin diseases], Ann Dermatol Venereol 2005 Mar;132(3):231-42.
-
2004Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus, Clin. Exp. Immunol. 2004 Jul;137(1):195-200.
-
2003Paraneoplastic pemphigus is associated with the DRB1*03 allele, J. Autoimmun. 2003 Feb;20(1):91-5.